sudden cardiac death in heart failure trial
Download
Skip this Video
Download Presentation
Sudden Cardiac Death in Heart Failure Trial

Loading in 2 Seconds...

play fullscreen
1 / 4

Sudden Cardiac Death in Heart Failure Trial - PowerPoint PPT Presentation


  • 146 Views
  • Uploaded on

SCD-HeFT. Sudden Cardiac Death in Heart Failure Trial. Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy. SCD-HeFT. 2,521 patients with moderately symptomatic CHF (NYHA Class II or III) and LVEF ≤35\% Randomized, double-blind, multicenter.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Sudden Cardiac Death in Heart Failure Trial' - aspasia


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
sudden cardiac death in heart failure trial
SCD-HeFT

Sudden Cardiac Death in Heart Failure Trial

Presented at

American College of Cardiology

Scientific Sessions 2004

Presented by Dr. Gust H. Bardy

scd heft
SCD-HeFT

2,521 patients with moderately symptomatic CHF (NYHA Class II or III) and LVEF ≤35%

Randomized, double-blind, multicenter

Conventional CHF Treatment + Placebo

Conventional CHF Treatment + ICD

Single lead implantable cardioverter defibrillator programmed for ventricular fibrillation (VF) treatment only

  • Conventional CHF Treatment + Amiodarone
  • Antiarrhythmic agent
    • 800 mg Week 1, 400 mg Week 2-4
    • Chronic therapy:
      • 200 mg/day if <150 lbs
      • 300 mg/day if 150-200 lbs
      • 400 mg/day if >200 lbs

Treatment

  • Endpoints (median 45.5 months):

All-cause mortality

Presented at ACC Scientific Sessions 2004

slide3
SCD-HeFT

All-cause mortality at 5 years

Amiodarone vs placebo

HR 1.06, p=0.529

ICD vs placebo

HR 0.77, p=0.007

  • Medication use at end of follow-up included 72% ACE-inhibitors, 78% beta-blockers, 80% loop diuretics, and 55% ASA
  • Prior duration of CHF was 24.5 months at baseline
  • No difference in all-cause mortality between amiodarone and placebo arm
  • Mortality was lower in ICD arm vs placebo

% Mortality

Presented at ACC Scientific Sessions 2004

slide4
SCD-HeFT
  • Among patients with NYHA Class II or Class III CHF and reduced left ventricular ejection fraction, treatment with an implantable ICD was associated with a reduction in all-cause mortality compared with placebo, but there was no difference between amiodarone and placebo
  • Secondary endpoint data not yet reported
ad